Heparin beyond anti-coagulation

Chen, Daohong

doi:10.1016/j.retram.2021.103300

Cited by 18 publications

(10 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Heparin‐derived compounds significantly contribute to the prevention and treatment of thrombotic events in pregnancy, respiratory inflammation, renal diseases, sepsis, and pancreatitis, among others. 21 Low‐molecular‐weight heparin also has a positive effect on thrombophilia IVF patients, 22 because it decreases coagulation in small blood vessels and increases trophoblast development. 23 This is in accordance with what we found, that treated thrombophilia patients had the same outcomes as normal patients.…”

Section: Discussionmentioning

confidence: 99%

The postpartum uterine ultrasonographic scale in assessment of uterine involution after cesarean section in treated thrombophilia pregnant patients at term

Filip

Covali

Socolov

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Pregnancy is a prothrombotic condition which can be abnormally exaggerated in women with thrombophilia. Methods In a prospective study, patients who delivered at term, by cesarean section, between 1 October 2017 and 1 December 2021, who already had a diagnosis of thrombophilia before coming to our hospital, were included in the study group ( n = 80). A similar number of nonthrombophilia patients ( n = 80) without any history of thrombotic events, age‐ and para‐matched with the study group, were included in the control group. The postpartum uterine ultrasonographic scale (PUUS) values, in the first 24–48 h, were correlated with the patients' data. Results The P‐LCR (platelet large cell ratio), was significantly higher in the treated thrombophilia group ( p = 0.042). There was no correlation between PUUS and complete blood count values, coagulation factors, maternal characteristics, or fetal outcomes, except for postpartum neutrophils ( p = 0.047) and postpartum platelet count ( p = 0.046). Conclusions Postpartum uterine involution was not significantly different, after cesarean section, between treated thrombophilia patients and nonthrombophilia patients. Involution correlated only with postpartum neutrophils and postpartum platelet count.

show abstract

Section: Discussionmentioning

confidence: 99%

The postpartum uterine ultrasonographic scale in assessment of uterine involution after cesarean section in treated thrombophilia pregnant patients at term

Filip

Covali

Socolov

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…For example, Heparin has served as a mainstream anticoagulant for nearly a century, and is used to prevent or to treat thrombotic events in various fields including coagulating complications in the patients with COVID-19 [ 19 ] . Recently, a RWD-based retrospective study found that low molecular weight heparin played an additive role in anti-inflammation by attenuating the cytokine storm upon associated with IL-6 down-regulation [ 20 ] .…”

Section: Re-purposing Therapeutic Indicationsmentioning

confidence: 99%

Real-world studies: bridging the gap between trial-assessed efficacy and routine care

Chen¹

2022

J Biomed Res

Self Cite

View full text Add to dashboard Cite

Even though randomized controlled clinical trials (RCTs) have been accepted as the gold standard for official assessment of novel interventions, there is a substantial gap between the efficacy observed in RCTs and the impact on clinical practice and in terms of patient benefit. While real-world studies (RWS) are emerging to confer valuable complementing evidence in this regard and beyond, the evolving role of RWS is yet to be agreed. This article delineates an updated profile of RWS covering effectiveness verification, rare adverse effects discovery, indication repurposing, to name a few. RWS tends not only to improve the efficiency of clinical investigations for regulatory approval, but also optimizes the whole-life cycle evaluation of biomedical/pharmaceutical products.

show abstract

“…When it occurs as hypercoagulation in pregnancy, VTE can lead to higher maternal morbidity. Heparin is safer than other anticoagulants when used during pregnancy [ 31 , 32 , 33 , 34 , 35 ]. Due to their animal origin and biosynthesis, GAGs have highly variable chain and sulfation patterns, which ultimately prevent the perfect purification of UFH.…”

Section: Anticoagulant Activitymentioning

confidence: 99%

Not Just Anticoagulation—New and Old Applications of Heparin

et al. 2022

View full text Add to dashboard Cite

In recent decades, heparin, as the most important anticoagulant drug, has been widely used in clinical settings to prevent and treat thrombosis in a variety of diseases. However, with in-depth research, the therapeutic potential of heparin is being explored beyond anticoagulation. To date, heparin and its derivatives have been tested in the protection against and repair of inflammatory, antitumor, and cardiovascular diseases. It has also been explored as an antiangiogenic, preventive, and antiviral agent for atherosclerosis. This review focused on the new and old applications of heparin and discussed the potential mechanisms explaining the biological diversity of heparin.

show abstract

Heparin beyond anti-coagulation

Cited by 18 publications

References 55 publications

The postpartum uterine ultrasonographic scale in assessment of uterine involution after cesarean section in treated thrombophilia pregnant patients at term

The postpartum uterine ultrasonographic scale in assessment of uterine involution after cesarean section in treated thrombophilia pregnant patients at term

Real-world studies: bridging the gap between trial-assessed efficacy and routine care

Not Just Anticoagulation—New and Old Applications of Heparin

Contact Info

Product

Resources

About